reproxalap
Aldeyra’s Reproxalap Demonstrates Efficacy in Reducing Eye Discomfort in New Phase 3 Study
Aldeyra Therapeutics, Reproxalap, Phase 3 Study, Eye Discomfort, Dry Eye Disease, FDA Rejection
Actionable Insights Powered by AI
Aldeyra Therapeutics, Reproxalap, Phase 3 Study, Eye Discomfort, Dry Eye Disease, FDA Rejection